Clinical Trials

Criteria

• Diagnosis of malignant disease
• No prior chemotherapy and scheduled to receive HEC (either cisplatin-containing regimen or anthracycline + cyclophosphamide [AC])
  • Cisplatin at a dose of ≥70mg/m^2, with or without other chemotherapy agent(s) OR
  • Anthracycline (60 mg/m^2) plus cyclophosphamide(600 mg/m^2)
• Age ≥18 years
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
• Required Initial Laboratory Values ≤ 120 days prior to registration
  • Serum Creatinine ≤2.0 mg/dL
  • Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic oxaloacetic transaminase (SGPT) ≤3 x Upper Limit of Normal (ULN)
  • Absolute neutrophil count (ANC) ≥1500/mm^3
• No nausea or vomiting ≤ 24 hours prior to registration
• Negative pregnancy test (serum or urine) done ≤7 days prior to registration, for women of childbearing potential only (per clinician discretion)
• No severe cognitive compromise
• No known history of CNS disease (e.g. brain metastases, seizure disorder)
• No treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone ≤30 days prior to registration or planned during protocol therapy
• No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue anti-emetic therapy)
• No concurrent use of amifostine
• No concurrent abdominal radiotherapy
• No concurrent use of quinolone antibiotic therapy
• No chronic alcoholism (as determined by the investigator)
• No known hypersensitivity to olanzapine
• No known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months.
• No history of uncontrolled diabetes mellitus (e.g. on insulin or an oral hypoglycemic agent)